EVALUASI PENGGUNAAN OBAT ANTITUBERKULOSIS (OAT) PADA PASIEN TB PARU DI PUSKESMAS PUNGGUR KABUPATEN LAMPUNG TENGAH PERIODE OKTOBER 2022 - OKTOBER 2023

Authors

  • Akhmad Rokiban 082184572502
  • Kiky Maykasari Universitas Tulang Bawang Lampung

Keywords:

Keywords       : Evaluation of Drug Use, OAT, Standard of Treatment, Pulmonary TB

Abstract

Tuberculosis is a infectious chronic disease caused by Mycobacterium tuberculosis. Based on WHO data the incidence of tuberculosis in Indonesia reached 842 thousand cases with a mortality rate of 107 thousand cases. To eradicate tuberculosis, one of which can be realized by the use of antituberculosis drugs by National Guidelines Standards. The purpose of this study was to evaluate the suitability of the use of OAT for pulmonary tuberculosis patients in Punggur Public Health Center, Central Lampung Regency from October 2022 - October 2023 based on the "National Guidelines for TB Prevention" by the Indonesian Ministry of Health in 2016.This type of research is a non-experimental study with a descriptive research design and retrospective approach of the medical record of pulmonary tuberculosis patients in Punggur Public Health Center, Central Lampung Regency, October 2022 - October 2023. Data were processed descriptively using Microsoft Excel program into a form of percentage table data.  The results showed that cases of pulmonary TB were more common in male patients at 61.4%. Patients who used type 1 OAT were 93.2% while patients who used category 2 OAT were 6.8%. The pattern of using OAT in pulmonary TB patients is KDT OAT as much as 100%. Based on conformity to the "National Guidelines for TB Prevention" by the Indonesian Ministry of Health, 2016, the results of the indication of conformity of 97.7%, the suitability of the combination of 100% and e suitability of the dose of 88.6% with the result of treatment 95.5% of patients cured and 4.5% of patients were declared not cured.

 

 

 

References

1. Stanley. 1999. Dasar Patologi Penyakit. Edisi 5. Sadikin H, editor. Jakarta: EGC. hlm 445.
2. World Health Organization. 2016. Global Tuberculosis Report. Geneva: World Health Organization.
3. World Health Organization. 2018. Global Tuberculosis Report. Geneva: World Health Organization.
4. Kementrian Kesehatan Republik Indonesia. 2018. Data dan Informasi Profil Kesehatan Indonesia. Jakarta: Kemenkes RI.
5. Kementrian Kesehatan Republik Indonesia. 2016. Permenkes RI No. 67 Tentang Pedoman Penanggulangan Tuberkulosis. Jakarta: Kemenkes RI.
6. World Health Organization. 2010. Global Tuberculosis Report. Geneva: World Health Organization


7. Kementrian Kesehatan Republik Indonesia. 2015. Peraturan Menteri Kesehatan Republik Indonesia Nomor 67 Tentang Penyelenggaraan Pelayanan Kesehatan Lanjut Usia Di Pusat Kesehatan Masyarakat. Jakarta: Kementrian Republik Indonesia.
8. Dipiro. 2015. Pharmacoteraphy Handbook Seventh Edition. USA: McGraw-Hill Company.
9. Bloomberg. 2012. The Rationale for Recommending Fixed-Dose Combination Tablets for Treatment of Tuberculosis. Bulletin of the World Health Organization.
10. Kementrian Kesehatan Republik Indonesia. 2014. Petunjuk Teknis Manajemen Terpadu Pengendalian Tuberkulosis Resistan Obat. Jakarta: Kementerian Kesehatan Republik Indonesia.
11. Sawitri. 2018. Evaluasi Ketepatan Obat dan Dosis Obat Antituberkulosis pada Pasien Anak Di Instalasi Rawat Jalan RSUD Dr. Moewardi Surakarta Periode 2016-2017. J Pharm Sci Clin Res. 02:93–103.

Downloads

Published

2024-04-30

How to Cite

EVALUASI PENGGUNAAN OBAT ANTITUBERKULOSIS (OAT) PADA PASIEN TB PARU DI PUSKESMAS PUNGGUR KABUPATEN LAMPUNG TENGAH PERIODE OKTOBER 2022 - OKTOBER 2023. (2024). Jurnal Farmasi IKIFA, 3(1), 59-70. https://epik.ikifa.ac.id/jfi/article/view/119